GSK

Experienced Life Sciences Leader Joins IPS as Regional Director to Lead New Australian Office

Retrieved on: 
Tuesday, February 6, 2024

IPS-Integrated Project Services, LLC , a leading provider of engineering , procurement , construction management , and validation (EPCMV) services, proudly announces the appointment of Gordon Nicholson as the Regional Director, ANZ (Australia, New Zealand), to lead IPS’ new Melbourne, Australia office.

Key Points: 
  • IPS-Integrated Project Services, LLC , a leading provider of engineering , procurement , construction management , and validation (EPCMV) services, proudly announces the appointment of Gordon Nicholson as the Regional Director, ANZ (Australia, New Zealand), to lead IPS’ new Melbourne, Australia office.
  • Before joining IPS, Gordon served in leadership roles across the APAC region from Singapore to Shanghai and Melbourne.
  • “Gordon’s appointment as Regional Director, ANZ allows us to further support our clients in bringing life-changing therapies to patients in Australia and beyond,” said Matthew Shippey, Managing Director, APAC.
  • Gordon’s leadership will be instrumental in fostering growth within the Australian market, positioning the company as a leading force in the life sciences and pharmaceutical manufacturing sectors.

GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk

Retrieved on: 
Tuesday, February 6, 2024

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted under Priority Review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease.

Key Points: 
  • GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted under Priority Review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease.
  • If approved, GSK’s RSV vaccine would be the first vaccine available to help protect this population.
  • AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is currently approved in the US in adults aged 60 and over for the prevention of lower respiratory tract disease (LRTD) caused by RSV.
  • GSK used a Priority Review Voucher to reduce the US FDA review period of a supplemental Biologics License Application (sBLA) by four months.

C3 AI Announces Fifth Annual AI Conference, C3 Transform 2024: Reshaping the World with Generative AI

Retrieved on: 
Monday, February 5, 2024

C3 AI (NYSE: AI), the Enterprise AI application software company, will host its fifth annual AI conference, C3 Transform 2024 , from March 5–7, 2024 in Boca Raton, Florida.

Key Points: 
  • C3 AI (NYSE: AI), the Enterprise AI application software company, will host its fifth annual AI conference, C3 Transform 2024 , from March 5–7, 2024 in Boca Raton, Florida.
  • This event brings together business leaders, technical experts, thought leaders, and C3 AI customers to discuss enterprise AI innovation, performance, and value; this year, the focus is on how generative AI is delivering enormous productivity and efficiency benefits across industries.
  • “At its core, C3 Transform is where the vision of enterprise AI comes to life,” said C3 AI CEO and Chairman Thomas M. Siebel.
  • C3 AI customers, including Holcim, GSK, and Con Edison, will also share invaluable insights from their digital transformation journeys, offering best practices for effectively building, scaling, and maintaining enterprise AI programs.

ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)

Retrieved on: 
Tuesday, February 6, 2024

The sheets allow people living with HIV to view the number of pills left and track their doses.

Key Points: 
  • The sheets allow people living with HIV to view the number of pills left and track their doses.
  • The FDA approved the Dovato blister pack on November 3, 2023.
  • ViiV Healthcare plans to offer the Dovato blister pack in some European markets in 2024.
  • ViiV Healthcare will continue to offer Dovato in the 30-count pill bottle.

Mondelēz International Appoints Brian McNamara to Board of Directors

Retrieved on: 
Friday, February 2, 2024

CHICAGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Mondelēz International, Inc. (Nasdaq: MDLZ) today announced the appointment of Brian McNamara to the Company’s Board of Directors, effective Feb. 1.

Key Points: 
  • CHICAGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Mondelēz International, Inc. (Nasdaq: MDLZ) today announced the appointment of Brian McNamara to the Company’s Board of Directors, effective Feb. 1.
  • McNamara has served as Chief Executive Officer of Haleon plc, formerly GSK Consumer Healthcare, since May 2022.
  • He currently sits on Haleon’s Board of Directors, as well as the Board of Directors of the Consumer Goods Forum.
  • McNamara’s appointment expands the size of the Company’s Board to 11 members, 10 of whom are deemed independent, including McNamara.

First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

Retrieved on: 
Monday, January 29, 2024

The clinical trial was initiated by and is being conducted at The University of Texas MD Anderson Cancer Center.

Key Points: 
  • The clinical trial was initiated by and is being conducted at The University of Texas MD Anderson Cancer Center.
  • LIXTE is providing LB-100; GSK is providing dostarlimab-gxly and financial support for the clinical trial.
  • The clinical trial (NCT06065462) is based on the observation by the lead clinical investigator of the trial, Amir Jazaeri MD, Professor of Gynecologic Oncology at MD Anderson, that a genetically acquired reduction in PP2A may enhance sensitivity to immunotherapyi.
  • This raises the possibility that reducing PP2A pharmacologically with LB-100 may enhance the anti-tumor effect of the PD-1 blocking monoclonal antibody, dostarlimab-gxly, in patients with OCCC lacking the genetic reduction in PP2A.

HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

Retrieved on: 
Thursday, January 18, 2024

BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer.

Key Points: 
  • BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer.
  • As part of a planned transition in connection with Mr. McLoughlin’s appointment, Co-founder and current Chief Operating Officer Dr. Aditya Kohli will remain a full-time executive with the company as Chief Business Officer, where he will be responsible for business development and corporate strategy.
  • Mr. McLoughlin has three decades of commercial and operational experience in vaccines, most recently as the Global Vaccine Commercialization Lead, RSV at GSK.
  • “We are excited to welcome Sean to HilleVax’s executive team as we continue to progress NEST-IN1, our Phase 2b clinical trial of HIL-214 for the prevention of moderate-to-severe norovirus-related acute gastroenteritis,” said Rob Hershberg, MD, PhD, Chairman and Chief Executive Officer of HilleVax.

Osivax Appoints Dr. Nicola Groth as Chief Medical Officer

Retrieved on: 
Thursday, January 25, 2024

Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Nicola Groth, MD, PhD to its executive committee as Chief Medical Officer.

Key Points: 
  • Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Nicola Groth, MD, PhD to its executive committee as Chief Medical Officer.
  • Dr. Groth joins Osivax as the company advances the development of its lead candidate, OVX836, a best-in-class broad-spectrum influenza vaccine candidate currently being evaluated in several Phase 2 clinical trials.
  • Dr. Groth takes over from Dr. Willems, whose contribution has been instrumental in advancing Osivax’ clinical strategy.
  • Nicola Groth holds a Doctor of Medicine and a PhD in Hygiene and Preventive Medicine from the University of Siena, Italy.

Third Rock Ventures Expands Senior Team with Seasoned Biotech Executives

Retrieved on: 
Thursday, January 25, 2024

Third Rock Ventures announced today that it has expanded its senior team with the addition and promotion of several industry leaders.

Key Points: 
  • Third Rock Ventures announced today that it has expanded its senior team with the addition and promotion of several industry leaders.
  • Jigar, who joined Third Rock in 2021 as a venture partner, has made significant contributions to the firm’s discovery and company creation activities.
  • Steve Paul, M.D., who has been affiliated with Third Rock since 2010, has re-joined as a venture partner.
  • Prior to Third Rock, Courtney was an early employee and the chief business officer of Beam Therapeutics.

ReAlta Life Sciences Strengthens Board of Directors with Appointment of Two Accomplished Biotechnology Innovators

Retrieved on: 
Wednesday, January 24, 2024

“We are delighted to welcome Dr. Baldoni and Dr. Van Gieson to our Board of Directors and look forward to their expertise as we continue to advance our EPICC platform beyond our current portfolio,” said Buzz Heidt, Chairman of ReAlta’s Board of Directors.

Key Points: 
  • “We are delighted to welcome Dr. Baldoni and Dr. Van Gieson to our Board of Directors and look forward to their expertise as we continue to advance our EPICC platform beyond our current portfolio,” said Buzz Heidt, Chairman of ReAlta’s Board of Directors.
  • Dr. Baldoni’s Platform Technology and Science team supported the development of small molecules, biopharmaceuticals and cell and gene therapy modalities from discovery through commercialization.
  • Dr. Baldoni stepped away from that leadership role in 2017 to start the first AI-driven drug discovery unit at GSK.
  • After retiring from GSK in 2019, he spent a year as the Chief Technology Officer of a stealth AI-enabled drug discovery startup.